IL291690A - Extracellular vesicle assemblies - Google Patents

Extracellular vesicle assemblies

Info

Publication number
IL291690A
IL291690A IL291690A IL29169022A IL291690A IL 291690 A IL291690 A IL 291690A IL 291690 A IL291690 A IL 291690A IL 29169022 A IL29169022 A IL 29169022A IL 291690 A IL291690 A IL 291690A
Authority
IL
Israel
Prior art keywords
extracellular vesicle
vesicle compositions
compositions
extracellular
vesicle
Prior art date
Application number
IL291690A
Other languages
English (en)
Hebrew (he)
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of IL291690A publication Critical patent/IL291690A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL291690A 2019-09-25 2022-03-24 Extracellular vesicle assemblies IL291690A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906018P 2019-09-25 2019-09-25
US201962906485P 2019-09-26 2019-09-26
PCT/US2020/052935 WO2021062317A1 (en) 2019-09-25 2020-09-25 Extracellular vesicle compositions

Publications (1)

Publication Number Publication Date
IL291690A true IL291690A (en) 2022-05-01

Family

ID=72840646

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291690A IL291690A (en) 2019-09-25 2022-03-24 Extracellular vesicle assemblies

Country Status (11)

Country Link
US (1) US20240099973A1 (enExample)
EP (1) EP4034081A1 (enExample)
JP (1) JP2022549328A (enExample)
KR (1) KR20220092654A (enExample)
CN (1) CN114727947A (enExample)
AU (1) AU2020355240A1 (enExample)
BR (1) BR112022005614A2 (enExample)
CA (1) CA3152478A1 (enExample)
IL (1) IL291690A (enExample)
MX (1) MX2022003570A (enExample)
WO (1) WO2021062317A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4196144A1 (en) 2020-08-17 2023-06-21 Codiak BioSciences, Inc. Methods of treating cancer
US11931458B2 (en) 2021-01-11 2024-03-19 Babak Ghalili Exosome systems, products and methods
KR20230166101A (ko) * 2021-04-01 2023-12-06 론자 세일즈 아게 세포외 소포 조성물
AR128774A1 (es) * 2022-03-18 2024-06-12 Merck Patent Gmbh Métodos y composiciones para purificar pequeñas vesículas extracelulares
WO2023195976A1 (en) * 2022-04-05 2023-10-12 Babak Ghalili Exosome systems, products and methods
US20250382613A1 (en) * 2022-06-30 2025-12-18 Lonza Sales Ag Methods of using extracellular vesicle-aso targeting stat6
CN115282065B (zh) * 2022-08-11 2024-03-15 顾帅 一种含间充质干细胞外泌体的冻干粉及其制备方法和应用
JP7730003B2 (ja) * 2023-02-10 2025-08-27 中国▲医▼薬大学 細胞外小胞／エクソソーム保存溶液及びその混合溶液
WO2024206778A1 (en) * 2023-03-30 2024-10-03 Exoone Bio. Co., Ltd. Radiolabeled exosome and method and kit for preparing same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
WO2009088401A2 (en) 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
MX2012004247A (es) * 2009-10-06 2012-06-25 Angiochem Inc Composiciones y metodos para el transporte de agentes terapeuticos.
CN107970451A (zh) 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
ES2982836T3 (es) 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
US20170340658A1 (en) 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
ES2764178T3 (es) 2014-12-16 2020-06-02 Kayla Therapeutics Dinucleótidos cíclicos fluorados para inducción de citocinas
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
UY36969A (es) 2015-10-28 2017-05-31 Novartis Ag Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
SG11201804117XA (en) * 2015-11-18 2018-06-28 Univ Georgia Neural cell extracellular vessicles
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
WO2018070939A1 (en) * 2016-10-12 2018-04-19 Agency For Science, Technology And Research Method for lyophilising an exosome
AU2017368050A1 (en) * 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
PT3512861T (pt) 2016-12-01 2021-04-29 Takeda Pharmaceuticals Co Dinucleotídeos cíclicos
MX2020001790A (es) * 2017-08-25 2020-07-22 Codiak Biosciences Inc Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana.
US20190175506A1 (en) * 2017-11-17 2019-06-13 Codiak Biosciences, Inc. Loading of Extracellular Vesicles through Imparting of Mechanical Shear
WO2019099942A1 (en) 2017-11-17 2019-05-23 Codiak Biosciences, Inc. Compositions of engineered exosomes and methods of loading luminal exosomes payloads
KR20200108275A (ko) * 2017-12-28 2020-09-17 코디악 바이오사이언시즈, 인크. 면역-종양학 및 항-염증 요법을 위한 엑소좀
GB201802163D0 (en) * 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
AU2019218991A1 (en) * 2018-02-12 2020-07-09 Lonza Sales Ag Methods and compositions for macrophage polarization
WO2019183578A1 (en) * 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
CN113286603B (zh) 2018-11-16 2025-07-22 隆萨销售股份公司 工程化的细胞外囊泡及其用途
US12233356B2 (en) * 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles

Also Published As

Publication number Publication date
BR112022005614A2 (pt) 2022-07-12
CN114727947A (zh) 2022-07-08
KR20220092654A (ko) 2022-07-01
WO2021062317A1 (en) 2021-04-01
MX2022003570A (es) 2022-07-11
EP4034081A1 (en) 2022-08-03
JP2022549328A (ja) 2022-11-24
AU2020355240A1 (en) 2022-04-21
CA3152478A1 (en) 2021-04-01
US20240099973A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
IL277344A (en) Extracellular vesicles containing agonist-STING
PL4328309T3 (pl) Kompozycja lipidowa
GB2586745B (en) Compositions
GB201916960D0 (en) Compositions
GB201811312D0 (en) Compositions
DK3924442T3 (en) Compositions
SG11202104306XA (en) Compositions
GB201915855D0 (en) An extracellular vesicle
IL289125A (en) the vehicles
SG11202003499YA (en) Immunomodulatory composition comprising lactobacillus-derived extracellular vesicles
SG11202009259VA (en) Compositions
PL4378314T3 (pl) Kompozycje herbicydowe
GB201908396D0 (en) Compositions
PL3563719T3 (pl) Kompozycje kosmetyczne
GB201803923D0 (en) Compositions
GB201910450D0 (en) Cosmetic compositions
GB201919234D0 (en) Compositions
GB201805676D0 (en) Compositions
GB201916122D0 (en) New compositions
IL305873A (en) Extracellular vesicle compositions
HK40078204A (en) Extracellular vesicle compositions
GB201906917D0 (en) Novel compositions
GB201819206D0 (en) Novel compositions
GB2570649B (en) Compositions
GB201916130D0 (en) New compositions